PureTech Health plc PureTech or the Company, a clinical-stage biotherapeutics company, announced today that its Founded Entity, Vedanta Biosciences, a clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, has raised $106.5 million to support pivotal-stage development of its lead candidate, VE303, for the prevention of recurrent CDI, and a Ph The VE303 study would be the first pivotal Phase 3 research of a treatment candidate based on a specified bacterial consortia, a next-generation approach to microbiome medicine pioneered by Vedanta.
New investors AXA IM Alts and The AMR Action Fund co-led the investor syndicate, which included current investors Bill & Melinda Gates Foundation, Skyviews Life Science, Reimagined Ventures, Fiscus Ventures, PEAK6, and Atlantic Neptune. New investors included K2 HealthVentures, Korea Investment Partners, Korea Investment & Securities Asia Ltd., and Korea Investment & Securities US, Inc., as well as existing investors such as PureTech Health’s co-founder, Revelation Partners, QUAD Investment Management, Seventure Partners, Hambro Perks, and Pfizer Inc.
PureTech is a biotherapeutics firm committed to redefining the treatment paradigm for life-threatening diseases. Through the knowledge of its seasoned research and development staff and its large network of scientists, physicians, and industry experts, the Company has built a broad and deep pipeline.
As of the most recent update by the Company, this pipeline, which is being advanced both internally and through PureTech’s Founded Entities, consists of 26 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization, and a third (KarXT) that will soon be filed for FDA approval.
